UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Implementation of Airy function using Graphics Processing Unit (GPU)

ITM Web of Conferences, 2020, Vol.32, p.3052

2020

Volltextzugriff (PDF)

Reactive molecules and microorganisms and copper intrauterine devices

International journal of gynecology and obstetrics, 2005-06, Vol.89 (3), p.282-283

2005

Volltextzugriff (PDF)

Chitosan functionalized halloysite nanotube/poly (caprolactone) nanocomposites for wound healing application

Applied surface science advances, 2021-12, Vol.6, p.100158, Article 100158

2021

Volltextzugriff (PDF)

Smart-NICs: Power Proxying for Reduced Power Consumption in Network Edge Devices

2008 IEEE Computer Society Annual Symposium on VLSI, 2008, p.75-80

2008

Volltextzugriff (PDF)

Power-Proxying on the NIC: A Case Study with the Gnutella File-Sharing Protocol

Proceedings. 2006 31st IEEE Conference on Local Computer Networks, 2006, p.519-520

2006

Volltextzugriff (PDF)

Air pollution and children’s health—a review of adverse effects associated with prenatal exposure from fine to ultrafine particulate matter

Environmental health and preventive medicine, 2021-12, Vol.26 (1), Article 72

2021

Volltextzugriff (PDF)

Mussaenda frondosa L. mediated facile green synthesis of Copper oxide nanoparticles – Characterization, photocatalytic and their biological investigations

Arabian journal of chemistry, 2021-06, Vol.14 (6), p.103184, Article 103184

2021

Volltextzugriff (PDF)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

HemaSphere, 2021-04, Vol.5 (4), p.e549-n/a

2021

Volltextzugriff (PDF)

Eliater: A Python package for estimating outcomes of perturbations in biomolecular networks

Bioinformatics (Oxford, England), 2024-08

2024

Volltextzugriff (PDF)

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

Leukemia research, 2020-07, Vol.94, p.106369-106369, Article 106369

2020

Volltextzugriff (PDF)

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

Leukemia research, 2018-01, Vol.64, p.10-16

2018

Volltextzugriff (PDF)

P33 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: T-CELL RECEPTOR SEQUENCING AND T-CELL MONOCLONALITY: A NOVEL BIOMARKER OF RESPONSE TO IVIG IN MDS PATIENTS WITH AUTOIMMUNE CYTOPENIAS

Leukemia research, 2021-09, Vol.108

2021

Volltextzugriff (PDF)

Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation

Leukemia research, 2021-09, Vol.108, p.106681, Article 106681.33

2021

Volltextzugriff (PDF)

In Utero Ultrafine Particulate Exposure Yields Sex- and Dose-Specific Responses to Neonatal Respiratory Syncytial Virus Infection

Environmental science & technology, 2022-08, Vol.56 (16), p.11527-11535

2022

Volltextzugriff (PDF)

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2024-01, Vol.403 (10423), p.249-260

2024

Volltextzugriff (PDF)

Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3026-3026

2019

Volltextzugriff (PDF)

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1357-1357

2018

Volltextzugriff (PDF)

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Blood, 2019-11, Vol.134 (Supplement_1), p.4268-4268

2019

Volltextzugriff (PDF)

MDS-156 Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S386-S386

2024

Volltextzugriff (PDF)

Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S191-S191

2024

Volltextzugriff (PDF)

CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

Journal of the National Comprehensive Cancer Network, 2024-04, Vol.22 (2.5)

2024

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(10)
Physical Sciences
(9)
Technology
(9)
Exact Sciences And Technology
(7)
Humans
(7)
Hematology
(6)
Chemistry
(5)
Engineering
(5)
India
(5)
Earth Sciences
(4)
Earth, Ocean, Space
(4)
Hematology, Oncology And Palliative Medicine
(4)
Myelodysplastic Syndromes
(4)
Telomerase
(4)
Tritium
(4)
Adult
(3)
Asia
(3)
Chemistry, Physical
(3)
Environmental Isotopes
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(5)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Implementation of Airy function using Graphics Processing Unit (GPU)

Reactive molecules and microorganisms and copper intrauterine devices

Chitosan functionalized halloysite nanotube/poly (caprolactone) nanocomposites for wound healing application

Smart-NICs: Power Proxying for Reduced Power Consumption in Network Edge Devices

Power-Proxying on the NIC: A Case Study with the Gnutella File-Sharing Protocol

Air pollution and children’s health—a review of adverse effects associated with prenatal exposure from fine to ultrafine particulate matter

Mussaenda frondosa L. mediated facile green synthesis of Copper oxide nanoparticles – Characterization, photocatalytic and their biological investigations

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Eliater: A Python package for estimating outcomes of perturbations in biomolecular networks

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

P33 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: T-CELL RECEPTOR SEQUENCING AND T-CELL MONOCLONALITY: A NOVEL BIOMARKER OF RESPONSE TO IVIG IN MDS PATIENTS WITH AUTOIMMUNE CYTOPENIAS

Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation

In Utero Ultrafine Particulate Exposure Yields Sex- and Dose-Specific Responses to Neonatal Respiratory Syncytial Virus Infection

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

MDS-156 Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge

Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge

CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

P732: ANALYSIS OF PATIENT‐REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS

Suchergebnisse filtern